US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Cybin Inc. Common Shares (NY:CYBN)

8.280 UNCHANGED
Last Price Updated: 8:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
41 42 Next >
News headline image
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
News headline image
Allied, Revive Therapeutics Among Top Psychedelic Movers Of Today ↗
GAINERS: Allied (OTC:ALID) shares closed up 29.44% at $0.56 
Via Benzinga
New Netflix Series to Explore the Use of Psychedelics for Mental Health
Via Investor Brand Network
News headline image
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today ↗
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 6.63% at $0.71 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From June 22, 2022 ↗
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 4.17% at $3.50 
Via Benzinga
News headline image
Cybin Closes Fiscal Year 2022, Reports Financial Results And Major Achievements ↗
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), a biopharma company focused on progressing “psychedelics to therapeutics” through proprietary drug discovery platforms announced its financial and business... 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Business Highlights, FY 2022 Results
Via Investor Brand Network
News headline image
10 Psychedelics CEOs To Pay Attention To In 2022 ↗
By Javier Hasse and Aaron Bry. 2020 and 2021 were defining years for the burgeoning psychedelics industry. In 2021 alone, more than $730 million were invested into various psychedelic companies, both... 
Via Benzinga
News headline image
Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
News headline image
Revive Therapeutics, Numinus Wellness Among Top Psychedelic Movers Of Today ↗
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 7.43% at $0.31 
Via Benzinga
Advances in Precision Medicine Boost Research on Psychedelics
Via Investor Brand Network
News headline image
Psychedelic Stock Gainers And Losers From June 17, 2022 ↗
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 5.69% at $0.67 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From June 16, 2022 ↗
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 3.08% at $10.05 LOSERS: 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright 1st Annual Mental Health Conference
Via Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright 1st Annual Mental Health Conference
Via Investor Brand Network
News headline image
Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022
From Cybin Inc.
Via Business Wire
News headline image
Psychedelic Stock Gainers And Losers From June 15, 2022 ↗
GAINERS: Cybin (AMEX:CYBN) shares closed up 9.11% at $0.62 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Collaborating to Progress Mission to Create Safe, Effective Therapeutics
Via Investor Brand Network
What You Should Know About Ego Death
Via Investor Brand Network
News headline image
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill ↗
Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider. 
Via Benzinga
World’s Richest Man Says Psychedelics Could Make a Real Difference in Mental Health
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – June 15, 2022 – Elon Musk believes that psychedelics and other plant-based drugs are better than pharma meds in treating a... 
Via FinancialNewsMedia
News headline image
Psychedelic Stock Gainers And Losers From June 14, 2022 ↗
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 9.90% at $9.44 
Via Benzinga
News headline image
ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today ↗
GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 1.06% at $0.81 LOSERS: 
Via Benzinga
WHO Wants Climate Change Efforts to Prioritize Mental Health
Via Investor Brand Network
Topics Climate Change
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
Good morning, traders! We're starting off the week with a dive into the biggest pre-market stock movers for Monday morning! 
Via InvestorPlace
News headline image
Cybin Moves Forward With Phase 1/2a Clinical Trial For Treatment Of Major Depressive Disorder ↗
Cybin Inc. 
Via Benzinga
News headline image
Psychedelic Stock Gainers And Losers From June 10, 2022 ↗
GAINERS: Cybin (AMEX:CYBN) shares closed up 6.16% at $0.67 
Via Benzinga
News headline image
Elon Musk Says Psychedelics Should Be Seriously Considered For Therapeutic Uses, Leading Chorus Of Celeb Support ↗
Elon Musk, the Tesla multi-billionaire investor and owner of the largest portion of Twitter (NYSE: TWTR) shares has been discus 
Via Benzinga
Four Key Takeaways from the Catalyst Summit in Canada
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Awarded Board Approval for CYB003 Phase 1/2a Clinical Trial
Via Investor Brand Network
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
41 42 Next >